These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 14694835

  • 1. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A.
    Med Klin (Munich); 2003 Oct 15; 98 Suppl 1():7-11. PubMed ID: 14694835
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S, Nakamura K, Takeuchi M.
    Med Hypotheses; 2005 Oct 15; 65(1):152-4. PubMed ID: 15893133
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U.
    Int J Cardiol; 2006 Feb 08; 107(1):11-20. PubMed ID: 16337493
    [Abstract] [Full Text] [Related]

  • 4. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS, Shankar RR, Shankar S, Shen C, Brizendine E, Baron A, McGill J.
    Diabetes Care; 2006 Sep 08; 29(9):2095-101. PubMed ID: 16936159
    [Abstract] [Full Text] [Related]

  • 5. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
    Leschke M.
    Med Klin (Munich); 2003 Oct 15; 98 Suppl 1():12-6. PubMed ID: 14694836
    [Abstract] [Full Text] [Related]

  • 6. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S, Chiasson JL.
    Curr Opin Pharmacol; 2005 Apr 15; 5(2):184-9. PubMed ID: 15780829
    [Abstract] [Full Text] [Related]

  • 7. Can reducing peaks prevent type 2 diabetes: implication from recent diabetes prevention trials.
    Haffner SM.
    Int J Clin Pract Suppl; 2002 Jul 15; (129):33-9. PubMed ID: 12166604
    [Abstract] [Full Text] [Related]

  • 8. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
    Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB.
    Am J Physiol Endocrinol Metab; 2004 Nov 15; 287(5):E906-11. PubMed ID: 15213063
    [Abstract] [Full Text] [Related]

  • 9. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M.
    Metabolism; 2005 Sep 15; 54(9):1168-73. PubMed ID: 16125528
    [Abstract] [Full Text] [Related]

  • 10. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
    Chiasson JL.
    Diabet Med; 1996 Sep 15; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
    [Abstract] [Full Text] [Related]

  • 11. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
    Azuma K, Toyofuku Y, Iesaki T, Otsuka A, Tanaka A, Mita T, Hirose T, Tanaka Y, Daida H, Kawamori R, Watada H.
    Biochem Biophys Res Commun; 2006 Jun 30; 345(2):688-93. PubMed ID: 16696939
    [Abstract] [Full Text] [Related]

  • 12. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?
    Scheen AJ.
    Diabetes Metab; 2007 Feb 30; 33(1):3-12. PubMed ID: 17258489
    [Abstract] [Full Text] [Related]

  • 13. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
    Yamagishi S, Nakamura K, Inoue H.
    Med Hypotheses; 2005 Feb 30; 65(2):377-9. PubMed ID: 15922116
    [Abstract] [Full Text] [Related]

  • 14. [Dangerous blood glucose peaks. Vascular damage even before diabetes].
    MMW Fortschr Med; 2003 Sep 04; 145(35-36):53. PubMed ID: 14584214
    [No Abstract] [Full Text] [Related]

  • 15. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW.
    Int J Clin Pract; 2005 Oct 04; 59(10):1218-28. PubMed ID: 16178991
    [Abstract] [Full Text] [Related]

  • 16. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C, Hofmann U, Paulwitz O.
    Diabetes Nutr Metab; 2004 Jun 04; 17(3):137-42. PubMed ID: 15334790
    [Abstract] [Full Text] [Related]

  • 17. Prevention of type 2 diabetes.
    Yale JF.
    Int J Clin Pract Suppl; 2000 Oct 04; (113):35-9. PubMed ID: 11965830
    [Abstract] [Full Text] [Related]

  • 18. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
    Hermanns N, Burkert A, Haak T.
    Exp Clin Endocrinol Diabetes; 2004 Jun 04; 112(6):310-4. PubMed ID: 15216448
    [Abstract] [Full Text] [Related]

  • 19. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun 04; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 20. Relationship between insulin resistance and left ventricular diastolic dysfunction in patients with impaired glucose tolerance and type 2 diabetes.
    Bajraktari G, Koltai MS, Ademaj F, Rexhepaj N, Qirko S, Ndrepepa G, Elezi S.
    Int J Cardiol; 2006 Jun 16; 110(2):206-11. PubMed ID: 16297997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.